Blau Farmacêutica Past Earnings Performance
Past criteria checks 2/6
Blau Farmacêutica has been growing earnings at an average annual rate of 14.7%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 10.3% per year. Blau Farmacêutica's return on equity is 12.4%, and it has net margins of 18.2%.
Key information
14.7%
Earnings growth rate
9.9%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | 10.3% |
| Return on equity | 12.4% |
| Net Margin | 18.2% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop
Feb 01
What Does The Future Hold For Blau Farmac êutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates
May 14Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
Feb 24Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely
Oct 14Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)
Aug 17Revenue & Expenses BreakdownBeta
How Blau Farmacêutica makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,373 | 250 | 279 | 0 |
| 30 Sep 23 | 1,352 | 317 | 246 | 0 |
| 30 Jun 23 | 1,351 | 312 | 231 | 0 |
| 31 Mar 23 | 1,352 | 354 | 217 | 0 |
| 31 Dec 22 | 1,407 | 363 | 214 | 0 |
| 30 Sep 22 | 1,390 | 314 | 231 | 0 |
| 30 Jun 22 | 1,348 | 313 | 213 | 0 |
| 31 Mar 22 | 1,354 | 301 | 210 | 0 |
| 31 Dec 21 | 1,366 | 325 | 204 | 0 |
| 30 Sep 21 | 1,354 | 354 | 193 | 0 |
| 30 Jun 21 | 1,338 | 335 | 186 | 0 |
| 31 Mar 21 | 1,289 | 309 | 175 | 0 |
| 31 Dec 20 | 1,182 | 254 | 162 | 0 |
| 30 Sep 20 | 1,066 | 238 | 136 | 0 |
| 30 Jun 20 | 1,029 | 214 | 131 | 0 |
| 31 Mar 20 | 1,008 | 203 | 128 | 0 |
| 31 Dec 19 | 978 | 200 | 127 | 0 |
| 30 Sep 19 | 987 | 186 | 146 | 0 |
| 30 Jun 19 | 938 | 177 | 148 | 0 |
| 31 Mar 19 | 819 | 129 | 145 | 0 |
| 31 Dec 18 | 782 | 123 | 142 | 0 |
| 30 Sep 18 | 677 | 90 | 134 | 0 |
| 30 Jun 18 | 616 | 78 | 124 | 0 |
| 31 Mar 18 | 634 | 110 | 127 | 0 |
| 31 Dec 17 | 618 | 103 | 127 | 0 |
| 31 Dec 16 | 431 | 32 | 125 | 0 |
| 31 Dec 15 | 379 | 22 | 108 | 0 |
| 31 Dec 14 | 299 | 17 | 78 | 0 |
| 31 Dec 13 | 271 | 15 | 53 | 0 |
Quality Earnings: BLAU3 has high quality earnings.
Growing Profit Margin: BLAU3's current net profit margins (18.2%) are lower than last year (25.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BLAU3's earnings have grown by 14.7% per year over the past 5 years.
Accelerating Growth: BLAU3's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BLAU3 had negative earnings growth (-31.3%) over the past year, making it difficult to compare to the Biotechs industry average (-2.9%).
Return on Equity
High ROE: BLAU3's Return on Equity (12.4%) is considered low.